NonamplificationERBB2genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies
出版年份 2016 全文链接
标题
NonamplificationERBB2genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies
作者
关键词
-
出版物
CANCER
Volume 122, Issue 17, Pages 2654-2662
出版商
Wiley
发表日期
2016-06-11
DOI
10.1002/cncr.30102
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations
- (2015) Jeffrey S. Ross et al. CANCER
- Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer
- (2015) Giovanni Ciriello et al. CELL
- Irreversible Multitargeted ErbB Family Inhibitors for Therapy of Lung and Breast Cancer
- (2015) Deepa Subramaniam et al. CURRENT CANCER DRUG TARGETS
- Analysis of different HER-2 mutations in breast cancer progression and drug resistance
- (2015) Zijia Sun et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Blockade of a Key Region in the Extracellular Domain Inhibits HER2 Dimerization and Signaling
- (2015) Javier A. Menendez et al. JNCI-Journal of the National Cancer Institute
- HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor
- (2015) Noa Efrat Ben-Baruch et al. Journal of the National Comprehensive Cancer Network
- Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring anERBB2S310F Mutation
- (2015) Saranya Chumsri et al. Journal of the National Comprehensive Cancer Network
- Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer
- (2015) V. Guarneri et al. ONCOLOGIST
- Blockade of a Key Region in the Extracellular Domain Inhibits HER2 Dimerization and Signaling
- (2015) Javier A. Menendez et al. JNCI-Journal of the National Cancer Institute
- Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab
- (2014) L. Castagnoli et al. CANCER RESEARCH
- HER2 aberrations in cancer: Implications for therapy
- (2014) Min Yan et al. CANCER TREATMENT REVIEWS
- Response of an ERBB2-Mutated Inflammatory Breast Carcinoma to Human Epidermal Growth Factor Receptor 2–Targeted Therapy
- (2014) Siraj M. Ali et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer
- (2014) Aleix Prat et al. JNCI-Journal of the National Cancer Institute
- Oncogenic Alterations in ERBB2/HER2 Represent Potential Therapeutic Targets Across Tumors From Diverse Anatomic Sites of Origin
- (2014) J. Chmielecki et al. ONCOLOGIST
- Treatment of Metastatic Extramammary Paget's Disease Associated With Adnexal Adenocarcinoma, With Anti-HER2 Drugs Based on Genomic Alteration ERBB2 S310F
- (2014) O. Vornicova et al. ONCOLOGIST
- Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive breast cancer: an NSABP Foundation Research Program phase I study
- (2013) Rachel C. Jankowitz et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Relapsed Classic E-Cadherin (CDH1)-Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 (ERBB2) Gene Mutations
- (2013) J. S. Ross et al. CLINICAL CANCER RESEARCH
- A High Frequency of Activating Extracellular Domain ERBB2 (HER2) Mutation in Micropapillary Urothelial Carcinoma
- (2013) J. S. Ross et al. CLINICAL CANCER RESEARCH
- A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer
- (2013) Miguel Martin et al. EUROPEAN JOURNAL OF CANCER
- Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
- (2013) Julien Mazières et al. JOURNAL OF CLINICAL ONCOLOGY
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
- (2013) Sandra M Swain et al. LANCET ONCOLOGY
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- (2013) Garrett M Frampton et al. NATURE BIOTECHNOLOGY
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2
- (2012) H. Greulich et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
- (2012) Ron Bose et al. Cancer Discovery
- Adjuvant Trastuzumab in HER2-Positive Breast Cancer
- (2011) Dennis Slamon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
- (2009) J. S. Ross et al. ONCOLOGIST
- Somatic mutations affect key pathways in lung adenocarcinoma
- (2008) Li Ding et al. NATURE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started